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A microsomal endoprotease specifically cleave8 isoprenylated peptides of the CAAX motif, such as N-acetyi-Sall-trans-farnesyl-L-cysteine (AFC- 
VIM), at the isoprenylated cysteine residue. It is shown here that endoproteolysis will d80 occur with peptides which are not of the CAAX type. 
Peptide substrates modeled after the Delta virus large antigen carboxyl-terminus (CRPQ) are endoproteolytically hydrolyzed by liver microsomes. 
AFC-RPQ is hydrolyzed with a &,, = 12.4 /IM and a V,, = 0.27 nmol/min/mg, and AGGC-RPQ is hydrolyzed with a KM = 7.9 PM and a 
V mDx = 0.042 nmol/min/mg. Moreover, a series of potent inhibitor8 of the endoproteolyais of AFC-AAX-containing peptides are ineffective at 
inhibiting the hydrolysis of AFC-RPQ and AGGC-RPQ, suggesting the existence of isoforms of the endoprotease. 
Endoproteolysis; Isoprenylated peptide; Inhibitor 
1. INTRODUCTION 
Protein isoprenylatioa represents abiochemical path- 
way essential in the activation of a diverse group of 
proteins. Included in this group are the heterotrimeric 
G proteins [1,2], the small G proteins (including ras) 
[3,4], and the nuclear lamins [5,6]. It has also recently 
been reported that the Delta virus large antigen is iso- 
prenylated [7]. Isoprenylation occurs at cysteine resi- 
dues close to the ~rboxyl-te~~us of the protein to be 
modified. Proteins with a ~arboxyl-te~nal CAAX 
(where C = cysteine, A = aliphatic amino acid, and X 
is an undefined amino acid) [4,8-IO] or, less frequently, 
a CXC sequence [I l-l 31 or a CXXX sequence [7], are 
first isoprenylated at the cysteine residue(s) with either 
all-trans-farnesyl (C15) or all-lrans-geranylgeranyl 
(C20) pyrophosphate [1416]. In the case of modifica- 
tions at a CAAX motif, proteolysis follows, to generate 
an isoprenylated cysteine residue as the new carboxyl- 
terminus [4]. This set of modifications is completed by 
the carbox~e~ylation of the isoprenylated cysteine 
residue [ 17-241. That this latter modification may be 
physiolo~~ly reversible is suggested by the discovery 
of a methylesterase specific for isoprenylated cysteine 
methyl ester derivatives [25]. 
Proteolysis occurs in mammals primarily by endopro- 
teolytic cleavage between the modified cysteine residue 
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and the adjacent aliphatic amino acid, to liberate the 
intact AAX tripeptide, as shown in Scheme 1 [26,27]. A 
liver microsomal endoproteolytic activity has been iden- 
tified using synthetic radiolabeled tetrapeptide sub- 
strates such as L-AFC-Val-Ile-Ser [26]. The isoprenyl 
group is essential for substrate activity, and either ster- 
eospecihcity or stereoselectivity is observed at AAX 
[28]. Potent inhibitors for the endoprotease have also 
been designed [29]. The analog containing BFC-statine- 
Val-Ile-Met (2) inhibits the endoprotease with a Ki = 64 
nM. The analogous pseudo~ptide ~(C~~-~~) (1) ana- 
log is almost as potent. The endoprotease substrates 
studied thus far fall into the CAAX motif type. A ques- 
tion that emerges is whether AFC-based tetrapeptides 
containing hydrophilic amino acids will be endoprote- 
olyzed, and whether the same endoprotease is capable 
of hydrolyzing the various substrates. The carboxyl- 
terminal sequence (Cys-Arg-Pro-Gln) of the Delta virus 
large antigen provides a pertinent example. It is demon- 
strated here that the tetrapeptides, AFC-RPQ (3) and 
AGGC-RPQ (4), are specifically processed by endopro- 
teolytic cleavage to produce AFC and the tripeptide 
RPQ. Thus, the endoproteolysis of non-CAAX se- 
quences proceeds as it does with CAAX sequences. 
Moreover, potent inhibitors of the endoproteolytic 
processing of isoprenylated CAAX-containing peptides 
do not interfere with the processing of AFC-RPQ and 




Fresh bovine calf liver was obtained from a local slaughterhouse. 
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N-Acetyl-L-proline and N-acetyl-rglutamine were purchased from the 
Sigma Chemicals Co. Geranylgeraniol was purchased from TCI Inc. 
All-trans-famesyl bromide, piperidine, and tritluoroacetic acid were 
acquired from Aldrich Chemical. [HIAcetic anhydride (spec. 
act. = 500 mCi/mmol) was purchased from New England Nuclear. 
N-Acetyl-L-arginine-L-proline-L-glutamine was synthesized by Dr. 
Chuck Dahl at the Harvard Medical School peptide synthesis facility. 
Proton nuclear magnetic resonance (‘H NMR) spectroscopy was re- 
corded on a Varian VRX 500s Spectrometer operating at a proton 
frequency of 499.843 MHz. Dimethylsulfoxide (DMSO-d,) was used 
as the ‘H NMR solvent. The residual proton absorption of the deuter- 
ated solvent was used as the internal standard. HPLC solvents were 
from J.T. Baker Inc. All chemicals and solvents purchased were of the 
highest purity commercially available. 
2.2. Protease assays 
Substrates were dissolved in DMSO and incubated with bovine liver 
microsomal membranes (0.2 mg of protein/ml) in 100 mM potassium 
phosphate buffer (pH 7.0) at 37°C for 60 min. The final DMSO 
concentration in the assays was 4% (v/v). The reaction was quenched 
with 500 ~1 of CHCldMeOH (1: 1, v/v), N-[‘H]AFC was extracted after 
thoroughly mixing for 1 min. Phase separation was achieved by adding 
500 ~1 of 1 M citric acid to the mixture. The chloroform layer was 
removed, dried, and evaporated under nitrogen. The residue was dis- 
solved in hexane/isopropanol/TFA (85: 15:O. 1) and non-radioactive 
AFC standard was added for UV detection (210 nm). Samples were 
injected on a normal-phase HPLC column (Dynamax 60A; Rainin) 
and elution was performed with the same solvent at a flow rate of 1.5 
ml/min. Radioactivity was determined using an on-line Berthold 
(Nashua, NH) LB 506-C HPLC radioactivity monitor. 
2.3. Syntheses 
Complete synthetic procedures used for the synthesis of N-[HI- 
acetyl-9all-rrans-famesyl-Lcysteine-L-ane 
and N-[‘H]acetyl-Sall-rrans-geranylgeranyl-L~ysteine-L-ar~nine-L- 
proline-tglutamine will be published separately. The ‘H NMR data 
and procedures for the last step in the synthesis of [3H]AFC-Arg-Pro- 
Gln and [‘H]AGGC-Arg-Pro-Gln are described below. 
2.3.1. Synthesis of iV-[3H]acetyl-S-all-trans-farnesyl-Lcysteine-L- 
arginine-L-proline-L-glutamine 
A mixture of S-all-trans-famesyl-L-cysteine-w-nitro-r.-arginine-~- 
proline-L-glutamine-p-nitrobenzyl ester (15 mg), [3Hlacetic anhydride 
(5 mCi, 500 mCi/mmol), and a catalytic amount of DMAP in meth- 
ylene chloride (8 ml) was stirred at room temperature for 28 h. The 
solvent was evaporated and the residue was purifed by silica gel 
chromatography (hexane./acetone 70~30, 50~50; then eluted with ace- 
tone and methanol successively). The acetylated peptide was re-dis- 
solved in 90% acetic acid (5 ml), and zinc dust (200 mg) was added. 
The mixture was stirred at room temperature for 22 h after which the 
zinc dust was removed by filtration. The aqueous olution was lyophil- 
ized, and the residue was purified by reverse-phase HPLC (column, 
C-18, 10.5 x 1 cm; flow rate, 2.5 ml/min; UV detection, 210 nm. Sol- 
vent A: 10 mM TFA in 20-100% water. Solvent B: 10 mM TFA in 
acetonitrile. Gradient program: 20% in 30 min, 100% B in 5 min, 
10&20% B in 5 mitt, 20% B in 5 min). The retention time for the 
product was 27.85 min. Yield, 0.78 mCi, 31%. ‘H NMR (500 MHz, 
DMSO-d,) of the authentic non-radioactive peptide: 8.2c8.11 (3 H, 
m), 8.08 (1 H, d, J = 8 Hz), 7.22 (1 H, s), 6.78 (1 H, s), 5.13 (1 H, t, 
J = 7.5 Hz), 5.05 (2 H, brs), 4.49 (1 H, t, J = 6 Hz), 4.40 (1 H, dd, 
J = 8.5, 14.5 Hz), 4.33 (1 H, t, J = 5 Hz), 4.09 (1 H, dd, J = 8, 14 Hz), 
3.63 (1 H, m), 3.50 (1 H, m), 3.23 (1 H, m), 3.12 (2 H, d, J = 7 Hz), 
3.07 (1 H, m). 2.70 (1 H, dd, J = 5.5, 13.5 Hz), 2.52 (1 H, dd, J = 4, 
13.5 Hz), 2.20-2.10 (3 H, m), 2.04-1.86 (13 H, m), 1.82 (3 H, s), 
1.78-1.64 (4 H, m), 1.61 (3 H, s), 1.59 (3 H, s), 1.53 (6 H, s). 
2.3.2. Synthesis of N-[3H]acetyl-Sall-trans-geranylgeranyl-L-cysteine- 
L-arginine-L-proline-L-glutamine 
A mixture of Sail-rrans-geranylgeranyl-L-cysteine-w_nn- 
ine-L-proline-rglutamine-p-nitrobenzyl ester (28 mg), [‘HIacetic anhy- 
dride (5 mCi, 500 mCi/mmol), and a catalytic amount of DMAP in 
methylene chloride (8 ml) was stirred at room temperature for 40 h. 
Solvent was evaporated and the residue was puritied by silica gel 
chromatography (hexane/acetone 70:30, 50:50; then eluted with ace- 
tone and methanol successively). The acetylated peptide was re-dis- 
solved in 90% acetic acid (5 ml) and zinc dust (200 mg) was added. The 
mixture was stirred at room temperature for 24 h after which the zinc 
dust was removed. The aqueous solution was lyophilized and the 
residue was purified by reverse-phase HPLC (column, C-18, 10.5 x 1 
cm; flow rate, 2.5 ml/min; UV detection, 210 nm. Solvent A: 10 mM 
TFA in water. Solvent B: 10 mM TFA in acetonitrile. Gradient pro- 
gram: 2&100% B in 30 min, 100% B in 5 mm, 10&20% B in 5 min, 
20% B in 5 min). The retention time for the product was 21.69 min. 
Yield, 0.51, 20%. ‘H NMR (500 MHz, DMSO-&) of the authentic 
non-radioactive peptide: 8.63 (1 H, brs), 8.2c8.12 (3 H, m), 8.08 (1 
H, d, J = 8 Hz), 7.21 (1 H, s), 6.78 (1 H, s), 5.13 (1 H, t, J = 7.5 Hz), 
5.05 (3 H, t, J = 6.5 Hz), 4.50 (1 H, brs), 4.40 (1 H, dd, J = 7.5, 12.5 
Hz), 4.33 (1 H, dd, J = 4, 8.5 Hz), 4.10 (1 H, dd, J = 8, 14 Hz), 3.64 
(1 H, m), 3.49 (1 H, m), 3.23 (1 H, m), 3.13 (2 H, d, J = 8 Hz), 3.04 
(1 H, m), 2.70 (1 H, dd, J = 5.5, 13.5 Hz), 2.52 (1 H, dd, J = 4, 13.5 
Hz), 2.22-2.10 (3 H, m), 2.04-1.88 (17 H, m), 1.82 (3 H, s), 1.78-1.64 
(4 H, m), 1.61 (3 H, s), 1.59 (3 H, s), 1.53 (9 H, s). 
3. RESULTS 
Previously we had found that tetrapeptides which 
conform to the AFCAAX or AGGCAAX motifs are 
endoproteolytically processed by bovine liver micro- 
somes after the modified cysteine residue to generate 
either AFC or AGGC [26,29]. Because the isoprenyl- 
ated Delta virus large antigen possesses a carboxyl-ter- 
minal sequence, CRPQ, we decided to determine if the 
liver enzyme(s) was able to cleave the appropriately 
modified sequence in the same way as tetrapeptides end- 
ing with CAAX. To these ends, the radioactive peptides 
shown in Scheme 2 were synthesized and studied as 
substrates for the liver microsomal enzyme(s). As 
shown in Fig. IA and B, both molecules proved to be 
enzymatically processed with the indicated KM and V,, 
+ AAX 
COaH 
Scheme 1. Endoproteolysis in the isoprenylation pathway. 
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Fig. I. (A) Protease activity with N-[3H]a~tyl-S-f~~y~~~-~s-~-~-L-Pra-L-Gln as substrate, ~ic~ae~~Mente~ and Eadie-Hofstee plots @set) 
of the fonnaticn of N-[‘H@FC as a function of ~-f3H]~tyl-~-f~yI-famesyI-~-Cys-L-Arg-l-Pro concentration. Symbols represent tea.a values 
of four determinations, and error bars represent the standard eviation from the mean. Error bars not shown are within symbok. (3) Roteasc 
activity with N-[3~]a~tyi-sp~r~yI-L-~s-L_ as substrate. ~cha~~~ente~ and ~~Hofst~ plots @set) of the forma- 
tion of N-@jAGGC as a function of N-~~Hfa~tyl-s-geranyige~~~l-L-Cyf-L-Arg-~-~~L-G~ ~n~t~tio~. Svmttofs represent mean values of 
four det~inations, and error bars represent the standard eviation from the mean. Error bars not shown are within symbols. 
values [Scheme 2). The enzymatic assays employed 
measure the formation of either [3H]AFC or 13H]AGGC 
by HPLC and so cannot be used to determine if the 
proteolytic cleavage is mediated in an endo or exo fash- 
ion. To determine the mechanism of the cleavage reac- 
tion, the products of the proteolysis reactian had to be 
modified in such a way that they could be separated and 
detected using HPLC techniques. Acetylation was the 
m~catio~ chosen for this purpose. Ar-Ac-Gln~ N-AG 
Pro, N-Ac-Arg, and N-AC- Arg-Pro-Gin could be read- 
ily separated by HPLC, as shown in Fig. 2A. The prote- 
olysis products of the farnesylated pcptide, 
[3H]AFCRPQ, were reacted with [3H]acetic anhydride. 
When the resultant radioactive peptides were separated 
by HPLC, the results shown in Fig. 2B were obtained. 
Clearly the tetrapeptide was endoproteolyzed to gener- 
ate [3H]N-Ac-RPQ as the major product (Fig. 2). There- 
fore, the proteolysis of the hydrop~~c peptide pro- 
ceeded in an endo manner, which liberates labeled AFC 
(or AGGC) and RPQ. 
It was of interest to determine if protease inhibitors, 
some of which inhibit the processing of isoprenyiated 
WAX-containing peptides, would interfere with the 
proteolysis of the hydrophilic isoprenylated peptides de- 
scribed here. First, none of the standard group-specific 
protease inhibitors tested, which included antipain, 
APMSF, aprotinen, bestatin, chymostatin, E-64, 
EDTA-Na,, leupeptin, pepstatin, phosphoramidon, 
and 1 ,lO-phe~ant~oline~ affected the proteolysis of 
AFC-RPQ. This result was also observed with the pro- 
teases which process the isoprenylated CAAX-contain- 
ing peptides [29]. However, the latter proteolytic activity 
was potently inbibited by a series of pseudo (u/) peptide 
and statine derivatives, some of which are shown below 
(Table I). None of these in~bito~ had any effect on the 
processing of AFC-RPQ when tested under conditions 
that potently inhibited the processing of AFC-VIM. 
This result is not consistent with the idea that a single 
enzyme is involved in the hydrolysis of all isoprenylated 
proteins, and shows that different forms of the protease 
are involved in the hydrolysis of hydrophobic and hy- 
drophilic peptides. 
4. DISCUSSION 
The experiments described here demonstrate that 
AFC-RPQ and AGGC-RPQ are cleaved endoprote- 
olytically by a liver microsomal activity. The amino acid 
sequence from which this peptide is derived is based on 
the isoprenylated Delta virus large antigen [7]. It is not 
clear whether this protein is farnesylated or geranylger- 
anylated [7]. Nevertheless, we report here that both the 
farnesylated and geranylgeranylated peptides are en- 
doproteolyzed, 
The sequence CRPQ, of course, does not fit in with 
the well-known CAAX motif, a common signal for iso- 
prenylation [33. Nevertheless, AFC-RPQ and AGGC- 
RPQ arc endoproteolyzed by the liver microsomal ac- 
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tivity, which brings up the question as to whether 
isoforms of the proteases exist, or whether the same 
Retention Time (min) 
Fig. 2. Formation of r.-Arg-r,-Pro-t.-Gln from AFC-L-Arg-~-pro-~- 
Gln. AFC-L-A~~-L-P~O-L-G~~ (10mM) was incubated with bovine 
liver microsomal membranes at 37’C for 1 h. The reaction was 
quenched with 200 ml of c~orofo~e~~ol(1: 1, v/v) and 200 ml 
of water. The aqueous layer was filtered and lyop~l~. Ten assay 
mixtures were pooled together. The residue was suspended in 3 ml of 
methylene chloride, and 2 mCi of [31-Bacetic anhydride (500 mCi/ 
mmol) was added. The mixture was stirred at room temperature over- 
night. Water (1 ml) was added and methylene chloride was evapo- 
rated. The aqueous part was lyophilized and the residue was re-dis- 
solved in 1 ml of water/acetonitrile (l:l, v/v). A mixture of 0.1 ml of 
this solution and a standard solution of Ac-Arg, AC-Pro, Ac-Gln, and 
Ac-Arg-Pro-Gln was injected onto a reverse-phase HPLC system 
(Rainin, C-18, 10.5 x 1 cm, UV detection at 210 mn, and flow rate 2.5 
ml/mm), starting the linear gradient at the same time. The gradient 
solvent for reservoir A was water containing 10 mM TFA, and for 
reservoir B was acetonitrile saturated with 10 mM TFA. Elution was 
O-10096 B in 35 min, 100% B in 10 min, loo-O% B in 5 min, and 10 
min re~~i~tion. Each fraction (1.25 ml) was collected and 
counted in ~intiBation fluid (12 ml) by using a Beckman LS-1800 
radioactivity counter. (A) HPLC trace: peak 1, AC-RPQ; 2, Ac-Arg; 
3, AC-Gin; 4, AC&O. (B) Radioactivity associated with the different 
fractions. 
Scheme 2. n = 1 (AFC-RPQ): Ks, = 12.38 f 0.54 PM, V_ = 
270.54 + 5.1 pmo~~mg. II = 2 (AGGC-RPQ): X;, = 7.90 k 1.X2 
IBM, Vm, = 41.77 & 2.21 pmoflmintmg. 
enzyme processes peptides both within the CAAX mo- 
tifs and without. This issue has been addressed with 
respect to the isoprenyl transferases. Sequent-sync 
isoforms certainly exist which use either farnesyl pyro- 
phosphate or geranylgeranyl pyrophosphate as sub- 
strates [U-16]. The methyltransferase [30] and meth- 
ylesterase are membrane-bound enzymes and have not 
yet been purified. Nevertheless, in the case of the meth- 
yltransferase, cross-inhibition studies indicate that the 
enzyme(s) is at least non-selective with respect to the 
geranylgeranyl moiety vs. the farnesyl moiety, and that 
individual isoforms with isoprene-specific activities may 
not exist [30]. Although the membrane-bound endopro- 
tease is readily solubil~ed with CHAPSQ (Chaudhu~, 
A. and Rando, R.R., ~published experiments), it has 
not been completely purified, so that the question of 
possible isoforms has not been approached. 
Potent tetrapeptide-based inhibitors of the endopro- 
tease with respect to its ability to hydrolyze AFC-VIM 
have been developed [29]* For example, 1 and 2 (Table 
1) have Ki values of 86 nM and 64 nM, respectively 1291. 
When the inhibitors were studied for their inhibitory 
potencies with respect o endoproteolysis of AFC-RPQ 
and, in some cases, AGGC-RPQ, they proved to be 
inert as inhibitors (Table I). The same ~on~ntrations of 
~ibitors potently inhibit the endoproteolysis of AFC- 
VIM. It can be concluded from these studies that the 
same form of the enzyme which hydrolyzes AFC-VIM 
and is susceptible to inhibition by analogs based on this 
sequence does not hydrolyze AFC-RPQ-containing 
peptides. Thus, isoforms of the endoprotease are likely 
to be present which could have important regulatory 
significance. The selective inhibition of these putative 
isoforms could be of substantial interest for uncovering 
the physiological role(s) of proteolysis in the isoprenyl- 
ation pathway. 
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Table I 
CAAX-based endooroteaae inhibitors do not affect processing of CRPQ-based substrates& 
October 1993 























50 I.LM 0 
50 PM 0 
The inhibitors were preincubated with the calf liver microsomal membrane (0.2 mg of protein/ml) in 100 mM phosphate buffer (prr 7) for 10 min. 
N-[3H]AFC-RPQ (10 ,uM) was added and the incubation was continued for 1 h. The work-up and enzymatic assays were performed as indicated 
in section 2. 
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